12 results on '"Ivana Lagreca"'
Number of results to display per page
Search Results
2. BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
- Author
-
Vincenzo Nasillo, Ivana Lagreca, Daniela Vallerini, Patrizia Barozzi, Giovanni Riva, Monica Maccaferri, Ambra Paolini, Fabio Forghieri, Stefania Fiorcari, Rossana Maffei, Silvia Martinelli, Claudio Giacinto Atene, Ilaria Castelli, Roberto Marasca, Leonardo Potenza, Patrizia Comoli, Rossella Manfredini, Enrico Tagliafico, Tommaso Trenti, and Mario Luppi
- Subjects
BTK inhibitors ,platelets ,ibrutinib ,acalabrutinib ,CLL ,invasive fungal infections ,Cytology ,QH573-671 - Abstract
In recent years, the introduction of new drugs targeting Bruton’s tyrosine kinase (BTK) has allowed dramatic improvement in the prognosis of patients with chronic lymphocytic leukemia (CLL) and other B-cell neoplasms. Although these small molecules were initially considered less immunosuppressive than chemoimmunotherapy, an increasing number of reports have described the occurrence of unexpected opportunistic fungal infections, in particular invasive aspergillosis (IA). BTK represents a crucial molecule in several signaling pathways depending on different immune receptors. Based on a variety of specific off-target effects on innate immunity, namely on neutrophils, monocytes, pulmonary macrophages, and nurse-like cells, ibrutinib has been proposed as a new host factor for the definition of probable invasive pulmonary mold disease. The role of platelets in the control of fungal growth, through granule-dependent mechanisms, was described in vitro almost two decades ago and is, so far, neglected by experts in the field of clinical management of IA. In the present study, we confirm the antifungal role of platelets, and we show, for the first time, that the exposure to BTK inhibitors impairs several immune functions of platelets in response to Aspergillus fumigatus, i.e., the ability to adhere to conidia, activation (as indicated by reduced expression of P-selectin), and direct killing activity. In conclusion, our experimental data suggest that antiplatelet effects of BTK inhibitors may contribute to an increased risk for IA in CLL patients.
- Published
- 2022
- Full Text
- View/download PDF
3. Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma
- Author
-
Giovanni Riva, Ivana Lagreca, Adriana Mattiolo, Daniela Belletti, Laura Lignitto, Patrizia Barozzi, Barbara Ruozi, Daniela Vallerini, Chiara Quadrelli, Giorgia Corradini, Fabio Forghieri, Roberto Marasca, Franco Narni, Giovanni Tosi, Flavio Forni, Maria Angela Vandelli, Alberto Amadori, Luigi Chieco-Bianchi, Leonardo Potenza, Maria Luisa Calabrò, and Mario Luppi
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2015
- Full Text
- View/download PDF
4. Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies
- Author
-
Ivana Lagreca, Vincenzo Nasillo, Patrizia Barozzi, Ilaria Castelli, Sabrina Basso, Sara Castellano, Ambra Paolini, Monica Maccaferri, Elisabetta Colaci, Daniela Vallerini, Patrizia Natali, Daria Debbia, Tommaso Pirotti, Anna Maria Ottomano, Rossana Maffei, Francesca Bettelli, Davide Giusti, Andrea Messerotti, Andrea Gilioli, Valeria Pioli, Giovanna Leonardi, Fabio Forghieri, Paola Bresciani, Angela Cuoghi, Monica Morselli, Rossella Manfredini, Giuseppe Longo, Anna Candoni, Roberto Marasca, Leonardo Potenza, Enrico Tagliafico, Tommaso Trenti, Patrizia Comoli, Mario Luppi, and Giovanni Riva
- Subjects
multiple myeloma ,Cancer Research ,Oncology ,ELISpot ,MGUS ,T cells ,immunity ,smoldering myeloma - Abstract
Multiple Myeloma (MM) typically originates from underlying precursor conditions, known as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM). Validated risk factors, related to the main features of the clonal plasma cells, are employed in the current prognostic models to assess long-term probabilities of progression to MM. In addition, new prognostic immunologic parameters, measuring protective MM-specific T-cell responses, could help to identify patients with shorter time-to-progression. In this report, we described a novel Multi-antigenic Myeloma-specific (MaMs) T-cell assay, based on ELISpot technology, providing simultaneous evaluation of T-cell responses towards ten different MM-associated antigens. When performed during long-term follow-up (mean 28 months) of 33 patients with either MGUS or SMM, such deca-antigenic myeloma-specific immunoassay allowed to significantly distinguish between stable vs. progressive disease (p < 0.001), independently from the Mayo Clinic risk category. Here, we report the first clinical experience showing that a wide (multi-antigen), standardized (irrespective to patients’ HLA), MM-specific T-cell assay may routinely be applied, as a promising prognostic tool, during the follow-up of MGUS/SMM patients. Larger studies are needed to improve the antigenic panel and further explore the prognostic value of MaMs test in the risk assessment of patients with monoclonal gammopathies.
- Published
- 2023
- Full Text
- View/download PDF
5. BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors
- Author
-
Robin Foà, Marco Zecca, Giuseppe Quartuccio, Ambra Paolini, Laura Rubert, Franco Narni, Lorenzo Iughetti, Ivana Lagreca, Patrizia Comoli, Leonardo Potenza, Mario Luppi, Fabio Forghieri, Patrizia Barozzi, Tommaso Trenti, Sabrina Basso, Daniela Vallerini, Monica Morselli, Ilaria Guido, Antonella Gurrado, Roberto Marasca, Elisabetta Colaci, Angela Cuoghi, Antonio Cuneo, Paola Bresciani, and Giovanni Riva
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,T cell ,Immunology ,Fusion Proteins, bcr-abl ,Priming (immunology) ,Biochemistry ,NO ,03 medical and health sciences ,In vivo ,Inside BLOOD Commentary ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Cytotoxic T cell ,Humans ,Protein Kinase Inhibitors ,Cells, Cultured ,Hematology ,business.industry ,leukemia ,Cell Biology ,Middle Aged ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Adoptive Transfer ,Leukemia ,030104 developmental biology ,medicine.anatomical_structure ,Female ,Bone marrow ,business ,Ex vivo ,T-Lymphocytes, Cytotoxic - Abstract
Although the emergence of bone marrow (BM)-resident p190BCR-ABL-specific T lymphocytes has been correlated with hematologic and cytogenetic remissions in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) undergoing maintenance tyrosine-kinase inhibitor treatment, little is known about the possibility of culturing these cells ex vivo and using them in T-cell therapy strategies. We investigated the feasibility of expanding/priming p190BCR-ABL-specific T cells in vitro by stimulation with dendritic cells pulsed with p190BCR-ABL peptides derived from the BCR-ABL junctional region and alternative splicing, and of adoptively administering them to patients with relapsed disease. We report on the feasibility of producing clinical-grade BCR-ABL-specific cytotoxic T lymphocytes (CTLs), endowed with antileukemia activity, from Ph+ ALL patients and healthy donors. We treated 3 patients with Ph+ ALL with autologous or allogeneic p190BCR-ABL-specific CTLs. No postinfusion toxicity was observed, except for a grade II skin graft-versus-host disease in the patient treated for hematologic relapse. All patients achieved a molecular or hematologic complete remission (CR) after T-cell therapy, upon emergence of p190BCR-ABL-specific T cells in the BM. Our results show that p190BCR-ABL-specific CTLs are capable of controlling treatment-refractory Ph+ ALL in vivo, and support the development of adoptive immunotherapeutic approaches with BCR-ABL CTLs in Ph+ ALL.
- Published
- 2017
6. Detection of Fusarium-specific T cells in hematologic patients with invasive fusariosis
- Author
-
Paola Bresciani, Monica Maccaferri, Daniele Campioli, Ivana Lagreca, Luigina Romani, Jean-Paul Latgé, Leonardo Potenza, Anne Beauvais, Fabio Forghieri, Elisabetta Colaci, Ambra Paolini, Patrizia Barozzi, Patrizia Comoli, Mario Luppi, Chiara Quadrelli, Tommaso Trenti, Angela Cuoghi, Franco Narni, Daniela Vallerini, Monica Morselli, Lorenzo Iughetti, Giovanni Riva, Valeria Coluccio, Monica Cellini, and Roberto Marasca
- Subjects
0301 basic medicine ,Fusarium ,Microbiology (medical) ,Infectious Diseases ,Antifungal Agents ,biology ,T-Lymphocytes ,030106 microbiology ,biology.organism_classification ,Microbiology ,03 medical and health sciences ,030104 developmental biology ,Fusariosis ,Humans ,Invasive Fusariosis - Published
- 2017
7. Circulating functional T cells specific to human herpes virus 6 (HHV6) antigens in individuals with chromosomally integrated HHV6
- Author
-
Elisabetta Colaci, Patrizia Barozzi, Giovanni Riva, Chiara Quadrelli, Franco Narni, Monica Maccaferri, Fabio Forghieri, Leonardo Potenza, Tommaso Trenti, Daniela Vallerini, Monica Morselli, Valeria Coluccio, Daniele Campioli, Mario Luppi, Annamaria Paolini, Ivana Lagreca, Roberto Marasca, R. Eccheli, and Patrizia Comoli
- Subjects
0301 basic medicine ,Microbiology (medical) ,Adult ,Male ,Herpesvirus 6, Human ,T-Lymphocytes ,Virus Integration ,030106 microbiology ,Biology ,T cell response ,03 medical and health sciences ,Antigen ,Chromosomes, Human ,Humans ,Child ,Aged ,Aged, 80 and over ,Human herpes virus ,General Medicine ,Middle Aged ,Virology ,030104 developmental biology ,Infectious Diseases ,Child, Preschool ,Immunology ,HHV-6 ,T-cell response ,U54 ,U90 ,chromosomal integration ,Female - Published
- 2016
8. The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungi
- Author
-
Elisabetta Colaci, Mario Luppi, Ambra Paolini, Roberto Marasca, Daniele Campioli, Paola Bresciani, Franco Narni, Luigina Romani, Patrizia Comoli, Monica Maccaferri, Angela Cuoghi, Leonardo Potenza, Fabio Forghieri, Jean-Paul Latgé, Patrizia Barozzi, Chiara Quadrelli, Monica Morselli, Tommaso Trenti, Daniela Vallerini, Valeria Coluccio, Giovanni Riva, and Ivana Lagreca
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,bone marrow ,medicine.medical_treatment ,antigen-specific T cells ,Invasive Aspergillosis ,Invasive Mucormycosis ,Aged ,Blood ,Bone Marrow ,CD8-Positive T-Lymphocytes ,Cohort Studies ,Female ,Fungemia ,Fungi ,Humans ,Interferon-gamma ,Middle Aged ,Veterinary (all) ,Infectious Diseases ,Biology ,03 medical and health sciences ,Internal medicine ,medicine ,Interferon gamma ,Hematology ,Effector ,General Medicine ,medicine.disease ,Phenotype ,respiratory tract diseases ,030104 developmental biology ,medicine.anatomical_structure ,Cytokine ,Immunology ,Bone marrow ,CD8 ,medicine.drug - Abstract
Bone marrow has already been described as an enrichment site for several antigen-specific T lymphocytes, but the presence of mould-specific T cells has never been investigated in the bone marrow. We have previously demonstrated that mould-specific T cells emerge in the peripheral blood of patients with invasive fungal infections (IFI) but tend to become undetectable after disease resolution. In seven patients with a history of IFI, we investigated the presence of mould-specific T cells secreting different cytokines in bone marrow and peripheral blood paired samples. The results showed that the frequencies of mould-specific T cells secreting the protective cytokine IFNγ are significantly higher in bone marrow (BM) and are mainly represented by CD8+ T lymphocytes with effector phenotype. A putative disappearance of such protective BM responses after myeloablative therapy could contribute to the increased risk of IFI in hematologic patients.
- Published
- 2016
9. Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma
- Author
-
Roberto Marasca, Barbara Ruozi, Flavio Forni, Chiara Quadrelli, Luigi Chieco-Bianchi, Alberto Amadori, Daniela Belletti, Franco Narni, Giovanni Tosi, Leonardo Potenza, Giorgia Corradini, Mario Luppi, Maria Luisa Calabrò, Laura Lignitto, Patrizia Barozzi, Adriana Mattiolo, Fabio Forghieri, Maria Angela Vandelli, Ivana Lagreca, Giovanni Riva, and Daniela Vallerini
- Subjects
Male ,medicine.medical_specialty ,Small interfering RNA ,Antineoplastic Agents ,Biology ,immune system diseases ,RNA interference ,hemic and lymphatic diseases ,Internal medicine ,Cell Line, Tumor ,Lymphoma, Primary Effusion ,PRDM1 ,medicine ,Humans ,RNA, Small Interfering ,Online Only Articles ,Hematology ,RNA ,PEL ,BLIMP1/PRDM1 ,Liposomes ,RNAi ,siRNA ,medicine.disease ,Lymphoma ,Neoplasm Proteins ,Repressor Proteins ,Cancer research ,Female ,Primary effusion lymphoma ,Positive Regulatory Domain I-Binding Factor 1 ,Plasmablastic lymphoma - Abstract
RNA interference (RNAi) has been suggested to represent a promising therapeutic approach in different disease settings. Primary effusion lymphoma (PEL) is a plasmablastic lymphoma consistently expressing B lymphocyte-induced maturation protein 1 (Blimp-1), a pivotal transcriptional regulator during
- Published
- 2015
10. Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study
- Author
-
Elisabetta Lugli, Elisabetta Colaci, Monica Morselli, Francesco Soci, Vincenzo Nasillo, Valeria Pioli, Ivana Lagreca, Fabio Forghieri, Roberto Marasca, Valeria Coluccio, Leonardo Potenza, Giovanni Riva, Sara Bigliardi, Patrizia Barozzi, Mauro Codeluppi, Daniela Vallerini, Erica Franceschini, Cristina Mussini, Chiara Quadrelli, Laura Arletti, Ambra Paolini, Mario Luppi, Andrea Gilioli, Franco Narni, Valeria Fantuzzi, Monica Maccaferri, and Andrea Messerotti
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,STEM-CELL TRANSPLANTATION ,RECIPIENTS ,Respiratory Syncytial Virus Infections ,Single Center ,Respirovirus Infections ,Virus ,Young Adult ,Internal medicine ,Epidemiology ,medicine ,Humans ,Respiratory system ,Aplastic anemia ,Respiratory Tract Infections ,Aged ,Retrospective Studies ,Aged, 80 and over ,Acute leukemia ,Leukemia ,Hematology ,Respiratory tract infections ,business.industry ,Anemia, Aplastic ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Parainfluenza Virus 3, Human ,Respiratory Syncytial Viruses ,Treatment Outcome ,Acute Disease ,Immunology ,Female ,business - Published
- 2015
- Full Text
- View/download PDF
11. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
- Author
-
Laura Arletti, Fabio Forghieri, Ivana Lagreca, Francesco Soci, Daniela Vallerini, Elisabetta Colaci, Cristina Mecucci, Emanuela Ottaviani, Valeria Fantuzzi, Valeria Pioli, Ambra Paolini, Vincenzo Nasillo, Patrizia Barozzi, Roberto Marasca, Patrizia Zucchini, Monica Morselli, Giovanna Leonardi, Franco Narni, Chiara Quadrelli, Goretta Bonacorsi, Valeria Coluccio, Laura Faglioni, Giorgia Corradini, Mario Luppi, Leonardo Potenza, Giovanni Riva, Giovanni Martinelli, Monica Maccaferri, Andrea Messerotti, Francesca Giacobbi, Brunangelo Falini, Sara Bigliardi, Forghieri, Fabio, Paolini, Ambra, Morselli, Monica, Bigliardi, Sara, Bonacorsi, Goretta, Leonardi, Giovanna, Coluccio, Valeria, Maccaferri, Monica, Fantuzzi, Valeria, Faglioni, Laura, Colaci, Elisabetta, Soci, Francesco, Nasillo, Vincenzo, Messerotti, Andrea, Arletti, Laura, Pioli, Valeria, Zucchini, Patrizia, Quadrelli, Chiara, Corradini, Giorgia, Giacobbi, Francesca, Vallerini, Daniela, Riva, Giovanni, Barozzi, Patrizia, Lagreca, Ivana, Marasca, Roberto, Narni, Franco, Mecucci, Cristina, Ottaviani, Emanuela, Martinelli, Giovanni, Falini, Brunangelo, Luppi, Mario, and Potenza, Leonardo
- Subjects
medicine.medical_specialty ,NPM1 ,Nucleophosmin ,Cancer Research ,Hematology ,integumentary system ,business.industry ,NPM1 mutations, MDS ,Myelodysplastic syndromes ,De novo acute ,Myeloid leukemia ,Gene mutation ,medicine.disease ,NPM1 mutations ,Oncology ,hemic and lymphatic diseases ,Internal medicine ,MDS ,medicine ,Cancer research ,business - Abstract
Nucleophosmin 1 (NPM1) gene mutations, resulting in aberrant cytoplasmic delocalization of NPM1 (NPMc+), are detected in about 30% of all de novo acute myeloid leukemia (AML) cases, and in 50–60% o...
- Published
- 2015
12. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL
- Author
-
Leonardo Potenza, Sabrina Basso, Ambra Paolini, Ilaria Iacobucci, Monica Morselli, Roberto Marasca, Patrizia Barozzi, Ivana Lagreca, Franco Narni, Fabio Forghieri, Valeria Fantuzzi, Mario Luppi, Daniela Vallerini, Monica Maccaferri, Andrea Messerotti, Eleonora Zanetti, Rossana Maffei, Giovanni Riva, Giovanni Martinelli, Patrizia Comoli, and Chiara Quadrelli
- Subjects
Cytotoxic ,T-Lymphocytes ,bcr-abl ,T cells ,Philadelphia positive ,Antineoplastic Agents ,Piperazines ,Persistence (computer science) ,Immunophenotyping ,Bcr abl1 ,Medicine ,Cytotoxic T cell ,Humans ,Elderly patient ,Protein Kinase Inhibitors ,Aged ,business.industry ,ALL ,BCR-ABL1 ,Imatinib ,MRD ,Benzamides ,Female ,Fusion Proteins, bcr-abl ,Immunologic Memory ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Pyrimidines ,Remission Induction ,T-Lymphocytes, Cytotoxic ,Fusion Proteins ,Hematology ,Immunology ,business ,Immunologic memory ,medicine.drug - Published
- 2014
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.